What matters just as much — if not more — is everything around that number: how customers adopt the product, how sales actually happen, and whether the company is building something that can scale inside a complex, regulated system.
The post Revenue Isn’t the Signal: What Early-Stage Health Tech Investors Should Be Watching Instead appeared first on MedCity News.
